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Background: The use of [18F] 2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for detection
of gastric cancer is often debated because FDG uptake varies for each patient. The purpose of this study was to
clarify the molecular mechanisms involved in FDG uptake.
Material and methods: Fifty patients with gastric cancer who underwent FDG-PET and gastrectomy were studied.
Snap-frozen tumor specimens were collected and examined by real-time PCR for relationships between maximum
standardized uptake value (SUV) and mRNA expression of the following genes: glucose transporter 1 (GLUT1),
hexokinase 2 (HK2), hypoxia-inducible factor 1α (HIF1α), and proliferating cell nuclear antigen (PCNA).
Results: Tumor size was the only clinicopathological parameter that significantly correlated with SUV. Transcripts for
the genes evaluated were about three-fold higher in malignant specimens than in normal mucosa, although only
HIF1α was significantly correlated with SUV. When divided into intestinal and non-intestinal tumors, there was a
significant correlation between SUV and tumor size in intestinal tumors. Interestingly, the weak association between
SUV and HIF1α expression in intestinal tumors was substantially stronger in non-intestinal tumors. No correlation
was found between SUV and mRNA expression of other genes in intestinal or non-intestinal tumors.
Conclusion: SUV was correlated with HIF1α, but not PCNA, HK2, or GLUT1 expression. FDG accumulation could
therefore represent tissue hypoxia rather than glucose transport activity for aggressive cancer growth.
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Radiology examinations provide important information for
cancer treatment, and [18F] 2-fluoro-2-deoxy-D-glucose
positron emission tomography (FDG-PET) differs from
conventional imaging through its use of cellular meta-
bolic characteristics to detect a variety of tumors and
metastases [1,2]. FDG-PET detection rates tended to
vary widely for gastric cancer, however, with 0–44%* Correspondence: izuishi@kms.ac.jp
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distribution, and reproduction in any mediumdetection in early stages and 34–94% detection in ad-
vanced stages [1,3-5]. Pseudolesions from physiological
FDG uptake prevent a more precise diagnosis [6]. More-
over, signet ring cell carcinoma was reported to signifi-
cantly lower the standardized uptake value (SUV) of
FDG compared to papillary or tubular adenocarcinomas
[1,7,8]. The usefulness of FDG-PET detection for gastric
cancer is thus a matter of debate.
Besides detecting tumors based on absolute value,
FDG-PET can also assess the response to chemotherapy
based on relative values before and after cancer treat-
ment [1]. Previous studies have suggested a significant
association between the metabolic changes observed by
FDG-PET and clinical or histopathological response
[9-11]. One report in particular predicted patientntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Takebayashi et al. Journal of Experimental & Clinical Cancer Research 2013, 32:34 Page 2 of 8
http://www.jeccr.com/content/32/1/34prognoses by detecting early changes in glucose uptake
after chemotherapy, which could help prevent the con-
tinuation of ineffective treatments. Ott et al. found that a
reduction in FDG uptake of more than 35% for metabolic
responders predicted a favorable response in gastric can-
cer patients two weeks after initiation of chemotherapy
[11], while metabolic non-responders or FDG non-avid
tumors received an unfavorable prognosis.
Cancer cells theoretically require a greater amount of
glucose consumption than healthy tissue because of
increased cell division [12,13] or anaerobic respiration in
tumors [14]. Many cancers increase glucose transport
through glucose transporter 1 (GLUT1) and glucose
phosphorylation by hexokinase (HK) [15-17]. A correl-
ation between FDG uptake and GLUT1 expression has
been found in gastric cancer patients [1,3,7,8], but these
studies were conducted by non-quantitative immunohis-
tochemistry analysis, such as negative or positive stain-
ing that can vary by evaluator. We therefore evaluated
the expression of glucose metabolism-related proteins
through quantitative reverse-transcription polymerase
chain reaction (qRT-PCR) and compared the results to
maximum SUV of FDG-PET. In addition, we also ana-
lyzed the expression of proliferating cell nuclear antigen
(PCNA) as a valid marker of proliferation [18] and
hypoxia-inducible factor 1 alpha (HIF1α) as a marker of
hypoxia [19] to elucidate either of these mechanisms, i.e.,
tumor proliferation or tumor hypoxia, contribute to FDG
uptake. We then discuss the significance and difficulties
involved with the clinical application of FDG-PET in
gastric cancer due to FDG uptake mechanisms.
Materials and methods
Patients
This retrospective study involved 50 patients (29 male and
21 female; mean age ± standard error of measurement
[SEM], 65.8 ± 1.4 years) with gastric cancer who under-
went same FDG-PET system before gastrectomy in
Kagawa University from July 2005 to March 2010. Tumor
specimens were snap-frozen at the time of surgery, and
stored at −80°C. Participants were divided into 25 cases of
intestinal tumors and 25 cases of non-intestinal tumors
based on histopathological diagnoses. When focal FDG
uptake was not found in the stomach, SUV was calculated
from a lesion determined by histology results after gastrec-
tomy. The International Union Against Cancer staging
system was used to determine clinicopathological parame-
ters associated with FDG uptake. The protocol was ap-
proved by the institutional review board of our institution,
and all patients provided written informed consent.
FDG-PET imaging
FDG-PET images were acquired with a PET scanner
(ECAT EXACT HR+, Siemens/CTI, Knoxville, TN, USA).Patients fasted at least five hours before FDG injection.
Images were reviewed on a Sun Microsystems workstation
(Siemens/CTI) along transverse, coronal, and sagittal
planes with maximum intensity projection images. The
images were then interpreted independently by two expe-
rienced nuclear medicine physicians blinded to the clinical
data. Tumor lesions were identified as areas of focally
increased FDG uptake exceeding that of surrounding nor-
mal tissue. A region of interest was placed over each lesion
to include the highest levels of radioactivity. Maximum
SUV was calculated with the following formula: SUV =
cdc/(di/w), wherein cdc is the decay-corrected tracer
tissue concentration (Bq/g), di is the injected dose (Bq),
and w is the patient’s body weight (g).
Immunohistochemical staining
Immunohistochemical staining was performed to deter-
mine GLUT1 and HK2 levels in gastric cancer tumors.
Briefly, resected specimens were fixed in 10% buffered for-
malin solution, embedded in paraffin, and sectioned at a
thickness of 4 μm. Slides were then incubated overnight at
room temperature with primary rabbit polyclonal antibody
against GLUT1 (1:200) or HK2 (1:100). Avidin-biotin-
peroxidase complex staining was performed according to
the manufacturer’s instructions (Santa Cruz Biotechnology,
CA, USA). Finally, nuclei were counterstained with
hematoxylin [20].
Real-time PCR
Total RNA was isolated from specimens by guanidinium
isothiocyanate-acid phenol extraction and quantified by
absorbance at 260 nm. Total RNA (1 μg) was used for
reverse transcription, and the resulting cDNA was analyzed
by real-time PCR with Power SYBR Green PCR Master
Mix and ABI Prism 7000 (Applied Biosystems, Foster, CA,
USA). Target-specific oligonucleotide primers and probes
were previously described [20,21]. 18S rRNA was used as
an endogenous control. Primers and probes for 18S rRNA
were obtained in a Pre-Developed TaqMan Assay Reagent
kit (Applied Biosystems, Stockholm, Sweden).
Statistical analysis
Data are expressed as mean ± SEM. Paired SUV results
were compared by student’s t-test. Multiple one-way
analysis of variance was used to assess differences in
mRNA levels. Correlation analyses were performed with
Spearman’s correlation analysis test. P<0.05 was consid-
ered statistically significant.
Results
Relationship between mean SUV and clinicopathological
data in gastric cancer
Of the 50 gastric cancer lesions, 45 showed focally
increased FDG uptake. The majority of patients had
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0.5 cm, with 16 cases classified as stage 4. The mean
SUV of stage 4 patients was 9.0 ± 1.3, while mean SUV
of stage 2 and stage 3 patients combined was 8.3 ± 0.6
(Figure 1a). When tumors were divided into intestinal
and non-intestinal tumors, mean SUVs were 7.8 ± 0.7
and 9.2 ± 1.0, respectively (Figure 1b). When divided by
median lymph node metastasis, 22 cases had less than
three and 28 cases had three or more; mean SUVs were
not significant at 9.4 ± 1.0 and 7.8 ± 0.7, respectively.
When divided by maximum median tumor diameter, 22
cases were less than 7.0 cm and 28 cases were 7.0 cm or
greater; mean SUVs were 7.0 ± 0.6 and 9.7 ± 0.9,
respectively (P < 0.05).
These results indicate that SUV was not dependent on
the number of lymph node metastases or cancer stage.
Maximum tumor diameter was the only parameter with
a significant difference. To more precisely determine its
correlation with SUV, we carried out quantitative analysis
(Figure 1c). Spearman’s correlation analysis indicated a
possible relationship between the factors (rs = 0.33,
P < 0.05).Expression of glucose transporter and glucose
metabolizing enzymes in gastric cancer
GLUT1 staining was seen in the cell walls, while HK2
staining was observed in the cytoplasm, of tubular
(Figure 2a1, 2b1) and poorly differentiated (Figure 2a2,
2b2) adenocarcinomas. Based on these results, specimens
were evaluated by qRT-PCR to determine the expressionFigure 1 Relationship between mean standardized uptake value and
uptake value (SUV) in stage 4 gastric cancer patients was not significantly h
tumors was not significantly greater than in non-intestinal tumors. (c) Spea
tumor size and mean SUV (rs = 0.33, P < 0.05). Values are expressed as me
Standardized Uptake Value.of glucose metabolism-related genes (HK1, HK2, GLUT1,
and glucose-6-phosphatase (G6Pase)). HK2 and GLUT1
levels were three-fold higher in cancerous tissue than in
normal mucosa (P < 0.001) (Figure 2c). G6Pase is a
gluconeogenic enzyme in the liver that reverses the reac-
tion metabolized by HK (glucose to glucose-6-phosphate)
[22]. Its expression appeared to decrease in cancerous tis-
sue, but not to a significant degree. In spite of the high
levels, no significant correlation was observed between
SUV and HK2 (Figure 2d) or GLUT1 (Figure 2e) expres-
sion. The glucose metabolic pathway in cancerous tissues
may be too complicated to regulate with the alteration of
a single molecule.Relationship between mean SUV and HIF1α or PCNA
expression in gastric cancer
To determine whether tumor proliferation or tumor hyp-
oxia contributes to FDG uptake, PCNA expression was
analyzed as a proliferation marker and HIF1α expression
as a hypoxia marker. The mRNA levels for both genes
were about three-fold higher in cancerous cells than in
normal mucosa (P < 0.001) (Figure 3a). To more precisely
determine the association of SUV with PCNA and HIF1α
mRNA expression, their correlation was quantitatively
analyzed. There was no correlation between PCNA ex-
pression and SUV (Figure 3b), but HIF1α expression
was correlated to SUV by Spearman’s correlation ana-
lysis (rs = 0.53, P < 0.01) (Figure 3c). There was no correl-
ation between PCNA expression and HIF1α expression
(data not shown).clinicopathological data in gastric cancer. (a) Mean standardized
igher than in stage 2 and stage 3 patients. (b) Mean SUV in intestinal
rman’s correlation analysis revealed a significant correlation between
an ± SEM. Int; Intestinal Type, Non-Int; Non-intestinal Type, SUV;
Figure 2 Expression of glucose transporter and glucose metabolizing enzymes in gastric cancer. (a) Glucose transporter 1 (GLUT1)
staining was strong in the cell walls of tubular (a1) and poorly differentiated adenocarcinomas (a2). (b) Staining for hexokinase 2 (HK2) was seen
in the cytoplasm of tubular (b1) and poorly differentiated adenocarcinomas (b2). (c) Increased mRNA expression of glucose metabolism-related
proteins was observed with HK2 and GLUT1, but not HK1 and Glucose-6-phosphatase (G6Pase). (d-e) Spearman’s correlation analysis found no
association between standardized uptake value (SUV) and HK2 (d) or GLUT1 (e) mRNA expression. Values are expressed as mean ± SEM.
*P < 0.05. GLUT1; Glucose transporter 1, G6Pase; Glucose-6-phosphatase, HK1; Hexokinase 1, HK2; Hexokinase 2, SUV; Standardized Uptake Value.
Figure 3 Relationship between mean standardized uptake value and hypoxia-inducible factor 1α or proliferating cell nuclear antigen
expression in gastric cancer. (a) mRNA levels for both genes were about three-fold higher in malignant specimens than in normal mucosa
(P < 0.001). (b) Spearman’s correlation analysis found no association between standardized uptake value (SUV) and proliferating cell nuclear
antigen (PCNA) mRNA expression. (c) A significant correlation was found between SUV and hypoxia-inducible factor 1α (HIF1α) mRNA expression
(r = 0.53, P < 0.01). Data are expressed as mean ± SEM *P < 0.05. HIF1α; Hypoxia-inducible factor 1α, PCNA; Proliferating cell nuclear antigen, SUV;
Standardized Uptake Value.
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in intestinal and non-intestinal gastric cancers
Although HK1 mRNA levels were similar, HK2 mRNA
levels were higher in both specimen types compared to
normal mucosa (P < 0.01). GLUT1 expression was signifi-
cantly higher in intestinal specimens than in normal
mucosa (P < 0.01), but was unchanged in non-intestinal
specimens (Figure 4). PCNA and HIF1α expression
increased three-fold in intestinal tumors (P < 0.01) com-
pared to normal mucosa.
Correlation between mean SUV and tumor size, HIF1α
mRNA levels, or PCNA mRNA levels in intestinal and non-
intestinal gastric cancers
To examine factors associated with SUV in intestinal
and non-intestinal gastric cancers, their correlation was
quantitatively analyzed. Spearman’s correlation analysis
indicated a possible relationship between SUV and
tumor size in intestinal specimens (rs = 0.50, P < 0.05)
(Figure 5a), but not non-intestinal specimens (Figure 5d).
The correlation between HK2 or GLUT1 expression and
SUV did not find in both cancers (data not shown). There
was no correlation between SUV and PCNA mRNA ex-
pression in either cancer type (Figure 5b and 5e). Inter-
estingly, the weak association between SUV and HIF1α
mRNA expression in intestinal specimens (rs = 0.48,
P < 0.05) (Figure 5c) was stronger in non-intestinal
specimens (rs = 0.56, P < 0.01) (Figure 5f ).
Discussion
FDG-PET has been used to not only detect cancerous le-
sions, but also predict therapeutic response after chemo-
therapy [1,11,23]. There are several possible mechanismsFigure 4 Expression of glucose metabolism-related proteins in intesti
levels were similar to those in normal mucosa, while HK2 mRNA levels wer
Glucose transporter 1 (GLUT1) expression increased more in intestinal tumo
intestinal tumors. Glucose-6-phosphatase (G6Pase) expression decreased, b
proliferating cell nuclear antigen (PCNA) and hypoxia-inducible factor 1α (H
(P < 0.01). Data are expressed as mean ± SEM *P < 0.05 (ANOVA). GLUT1; G
inducible factor 1α, HK1; Hexokinase 1, HK2; Hexokinase 2, PCNA; Proliferatibehind its ability to reveal malignant potential or cancer
cell activity. Our results found that SUV in stage 4 gastric
cancer patients was no higher than in stage 2 and stage 3
patients, and the main tumor SUV did not reflect the
number of lymph node metastases. Only tumor size was
associated with SUV, a correlation also reported in breast,
pancreatic, and colorectal cancers [20,24,25]. These find-
ing narrow the FDG-PET mechanism possibilities by
suggesting that SUV reflects tumor size rather than tumor
cell activity for each cancer stage.Over expression of glucose metabolism-related protein in
tumors
A molecular explanation for high FDG uptake in cancer-
ous tissues is the overexpression of GLUT1, the molecule
reported to be responsible for FDG uptake in various
cancers [20,26]. Glucose uptake ability as assessed by
FDG-PET was significantly correlated with the doubling
time of tumors [27] because increased uptake can provide
additional energy to support tumor growth. Yamada et al.
[7] determined from immunohistochemistry that GLUT1
expression was an important factor for FDG uptake and
also a prognostic tool for gastric cancer. Alakus et al. [3]
similar reported that FDG uptake in gastric cancer is
dependent on the degree of GLUT1 staining. Our immu-
nohistochemical staining also showed strong GLUT1
expression in cell membranes, as well as GLUT1 mRNA
expression 3.3-fold greater in tumors than the surround-
ing mucosa; however, Spearman’s correlation analysis did
not find a relationship between GLUT1 expression and
SUV. HK2 also plays an important role in FDG catabol-
ism, with its overexpression significantly associated withnal and non-intestinal gastric cancers. Hexokinase 1 (HK1) mRNA
e higher in both intestinal and non-intestinal gastric cancers (P < 0.01).
rs than in normal mucosa (P < 0.01), but were unchanged in non-
ut the difference was not significant. The mRNA expression of
IF1α) increased more than three-fold compared to normal mucosa
lucose transporter 1, G6Pase; Glucose-6-phosphatase, HIF1α; Hypoxia-
ng cell nuclear antigen, SUV; Standardized Uptake Value.
Figure 5 Correlation between mean standardized uptake value and tumor size, hypoxia-inducible factor 1α mRNA levels, or
proliferating cell nuclear antigen mRNA levels in intestinal and non-intestinal gastric cancers. (a) Spearman’s correlation analysis indicated
a possible correlation between standardized uptake value (SUV) and tumor size in intestinal cancers (rs= 0.50, P < 0.05). (b) No association was
found between SUV and proliferating cell nuclear antigen (PCNA) mRNA expression. (c) A weak association was observed between SUV and
hypoxia-inducible factor 1α (HIF1α) mRNA expression (rs = 0.48, P < 0.05). (d) In non- intestinal cancer specimens, SUV was not correlated to
tumor size. (e) No association was found between SUV and PCNA expression. (f) A significant correlation between SUV and HIF1α mRNA
expression was observed (rs = 0.56, P < 0.01). Data are expressed as mean ± SEM. *P < 0.05. HIF1α; Hypoxia-inducible factor 1α, PCNA;
Proliferating cell nuclear antigen, SUV; Standardized Uptake Value.
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overexpression in gastric cancer tumors, but there was
again no correlation between HK2 expression and SUV.
Other complicated mechanisms, such as blood flow, accu-
mulation of inflammatory cells, and cellularity might be
also contribute to the intensity of FDG uptake based on
malignant energy demand [20].
Hypotheses of the increased glucose uptake in tumor
Two major hypotheses have been presented to explain the
increased glucose uptake in cancerous tissue, either that
enhanced glucose consumption is associated with tumor
proliferative activity [12,13] or that tissue hypoxia induces
anaerobic glycolysis to increase glucose metabolism [14].
Our results indicate that FDG uptake associated signifi-
cantly with hypoxia, reflected by HIF1α expression, but
not with proliferative activity, reflected by PCNA expres-
sion; these gastric cancer findings correspond to our previ-
ous report on colorectal cancer [20]. Rapid cancer growthinduces a hypoxic environment in tumors. HIF1α acts as a
sensor for hypoxic stress and upregulates angiogenic
factors and promotes transcription of several genes, in-
cluding glucose transporters and glycolytic enzymes such
as GLUT1 and HK, for tumor survival [29]. HIF1α may
also be involved with oncogenic alterations to glucose
metabolism because it activates cancer-related gene tran-
scription and affects pathways such as angiogenesis, cell
survival, glucose metabolism, and cell invasion [30]. HIF1α
overexpression has been associated with increased patient
mortality rates in several cancers, while inhibited expres-
sion reduced tumor growth in an in vitro study [30].
HIF1α could thus play a central role in cancer progression
that FDG uptake represents.
Histological differences in the expression of glucose
metabolism-related proteins
The non-intestinal gastric cancers, signet ring cell car-
cinoma and mucinous carcinoma, presented a very low
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due to low GLUT1 expression [1,3,7,8]. Berger et al.
reported that FDG-PET revealed an unusually high per-
centage (41%) of false-negative results in carcinoma with
mucin. There was a positive correlation of FDG uptake
with tumor cellularity but a negative correlation with the
amount of mucin [31]. Therefore, non-intestinal gastric
cancers, which have characters of low cellularity and/or
high mucin content, do not show high FDG uptake.
Alakus et al. has reported that over expression of
GLUT1 in papillary/tubular adenocarcinoma and signet
ring cell carcinoma was 94% and 24%, respectively [3].
Our results also indicate that GLUT1 expression in non-
intestinal cancers was lower than in intestinal cancers.
However, the reason why such aggressive cancers
showed low GLUT1 expression is unknown. A previous
study found that glutamine metabolism is upregulated in
gastric cancer [32]. Gastric cancer cells use glutamine as
an energy source in a hypoxic tumor microenvironment,
which may eliminate the necessity for glucose transport.
This metabolic alteration accompanied with malignant
transformation has been reported in other cancers [33].
Interestingly, a glutamine-based PET is being developed;
if successful, this contradiction could be disproved in the
future.
On the other hand, HIF1α expression correlated with
SUV in both types, although a more significant correl-
ation was seen in non-intestinal specimens. The non-
intestinal tumors may have been influenced more by
hypoxia derived from tumor fibrosis due to a scattering
tumor growth pattern than hypoxia due to increased
tumor size. Further research will be needed to determine
the exact reason.
Limitations of this study
There are several limitations in our study. First, we
examined 50 cases of gastric cancer patients. The few-
ness of cases affects the statistical analysis and makes it
difficult to get firm results in association of FDG uptake
and the expression of the proteins. Second, we could not
exclude the possibility of contribution of physiological
FDG uptake in normal stomach on cancerous lesion.
Finally, our results did not show the direct physiological
relationship between HIF1α as a marker of hypoxic
condition and FDG accumulation.
Conclusions
The usefulness of FDG-PET in the detection of malig-
nant tumors or prediction of prognoses has been
widely reported. However, our results indicate that the
degree of FDG accumulation does not always suggest a
prognosis in gastric cancer. This study is the first to
show the correlation by evaluating FDG uptake in a
quantitative manner. Upregulation of glucose transportdue to increased GLUT1 expression was not an explan-
ation for the different FDG uptakes observed, although
tumor hypoxia and HIF1α expression may provide a rea-
sonable mechanism. Further investigation is needed to
confirm these results, but metabolic alternation through
HIF1α induction in tumor hypoxia could increase FDG
uptake in gastric cancer.
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